Answers are grounded in this paper and cite their sources.
The development of effective vaccines against Entamoeba histolytica remains a major challenge, particularly for preventing amoebic liver abscess (ALA). In this study, carbon nanotubes (CNTs) were evaluated as nanocarriers through bioconjugation with L220-derived peptides (PL220-CNTs). CNTs were synthesized, purified, and characterized, confirming successful bioconjugation (42%). In vitro, PL220-CNTs exhibited negligible cytotoxicity in J774 macrophages and induced morphological changes characterized by cytoplasmic prolongations and phagosome-like structures. In vivo, subcutaneous immunization of hamsters induced antigen-specific responses, including splenocyte proliferation and increased IL-17A production, suggesting the participation of an IL-17A-associated immune response. Notably, animals immunized with PL220-CNTs exhibited limited antibody production against L220-derived peptides, suggesting a predominantly cellular immune response. PL220-CNT immunization conferred complete protection against ALA following intrahepatic challenge, whereas L220 alone provided partial protection. Histological analyses revealed preservation of hepatic architecture and reduced inflammatory damage in PL220-CNT-immunized animals. Overall, these findings support the potential of bioconjugated CNTs as immunomodulatory nanoplatforms for vaccine development against amoebiasis and other infectious diseases.
No takes yet. Share an insight, caveat, or question.
Velarde-Calderón et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: